Advertisement

Suboptimal Use of Initial Chemotherapy in Newly Diagnosed AML

Advertisement

Key Points

  • Chemotherapy was not used in 25% of patients with newly diagnosed disease.
  • Factors associated with nonuse included racial, insurance and income status, and treatment facility type.

In a study of National Cancer Database data reported in Blood Advances, Bhatt et al found that 25% of patients with newly diagnosed acute myeloid leukemia (AML) did not receive initial chemotherapy, despite evidence that chemotherapy is associated with a survival benefit and improvement in symptoms in this setting. Prior studies have found lower use of chemotherapy with increasing age and comorbidities. The current study confirmed these findings, and also found that use was affected by socioeconomic and health system factors.

Study Details

The study included 61,775 adults with AML diagnosed between 2003 and 2011 from the National Cancer Database. Multivariable logistic regression modeling was used to determine the association between receipt of chemotherapy and variables including disease characteristic and clinical, socioeconomic, and health system factors. Nearly all patients (97.7%) received care in urban facilities.  

Among all patients, 15, 608 (25.3%) did not receive chemotherapy, and 46,167 (74.7%) received chemotherapy. Chemotherapy was initiated within a median of 4 days after diagnosis (interquartile range = 2–10 days; range = 0–1,098 days).

Among patients receiving chemotherapy, treatment was multiagent in 74.9%, single-agent in 21.8%, and unspecified in 3.3%. Among patients not receiving chemotherapy, reasons cited for not receiving treatment were unspecified in 72.8% of cases, contraindications including comorbidities or advanced age in 11.4%, patient or family refusal in 11.3%, death before therapy in 3.8%, and recommended but not given for unspecified reasons in 0.7%. For patients given vs not given chemotherapy, 1-month mortality was 11.8% vs 53.6%, and 5-year overall survival was 25.8% vs 2.6%.

On univariate analysis, factors significantly associated with lower likelihood of receiving chemotherapy were increasing age (particularly age ≥ 60 years), higher Charlson comorbidity score, therapy-related AML or intermediate/high-risk AML vs core binding factor AML and acute promyelocytic leukemia, female sex, white race, lower educational status, lower income, uninsured status, and receipt of care in nonacademic centers and low volume hospitals. Chemotherapy was more likely to be received by patients traveling longer distances for care.

Multivariate Analysis

On multivariate analysis, two-way interactions for age by insurance status (P < .001) and age by Charlson comorbidity score (P < .0001) were statistically significant. The likelihood of receiving chemotherapy was reduced with increasing age, higher Charlson comorbidity score, and uninsured or Medicare insurance status (all P < .0001).

Likelihood of chemotherapy use differed significantly according to AML subtypes (overall P < .0001). For example, chemotherapy use was less likely for therapy-related AML (odds ratio [OR] = 0.62, 95% confidence interval [CI] = 0.51–0.74, vs other intermediate-/high-risk disease; OR =  0.54 , 95% CI =0.44–0.67, vs acute promyelocytic leukemia) and for intermediate-/high-risk AML (OR = 0.88, 95% CI = 0.80–0.97, vs acute promyelocytic leukemia); chemotherapy use was more likely in patients with core binding factor AML vs therapy-related AML (OR = 2.32, 95% CI = 1.82–2.96 ), other intermediate/high-risk disease (OR = 1.43, 95% CI = 1.22–1.68), and acute promyelocytic leukemia (OR = 1.26, 95% CI = 1.05–1.52).

Lower hospital volume was associated with lower likelihood of chemotherapy receipt (OR = 1.02, P< .0001, for hospital volume as a continuous variable). Female sex (OR =1.07, P = .001, for male vs female), African American race (OR = 0.84, 95% CI = 0.73–0.96, vs other; OR = 0.85, 95% CI = 0.78–0.93, vs white; overall P = .0009), and lower income status (eg, OR =0.80, 95% CI = 0.74–0.87, for annual household income of $30,000 vs ≥ $46,000; overall P < .0001) also were independently associated with reduced likelihood of receiving chemotherapy.

Chemotherapy use was significantly more likely for patients treated in academic vs nonacademic centers (OR = 1.51, P <.0001) and for patients who traveled longer distances to receive treatment (eg, OR = 1.26, 95% CI = 1.18–1.34, for 12–34.7 vs 0–4.9 miles; OR = 1.41, 95% CI = 1.31–1.52, for ≥ 34.8 vs 0–4.9 miles; overall P < .0001).

The investigators concluded, “… [A] quarter of patients with newly diagnosed AML do not receive chemotherapy in the United States. Whereas the lower receipt of chemotherapy is expected among older patients, patients with significant comorbidities, and those with high-risk AML, racial, insurance and income status, and facility type also influenced the likelihood of receiving chemotherapy. These findings raise a possibility of leukemia care disparity based on socioeconomic and health system factors. Early diagnosis of AML, multidisciplinary management of leukemia emergencies and comorbidities, and strengthening the partnership between academic leukemia experts and community oncologists are some of the potential ways to increase the use of chemotherapy…. Chemotherapy use should be maximized, especially as we enter the era of more effective and better tolerated novel and molecularly targeted therapies.”

Vijaya Raj Bhatt, MD, of the University of Nebraska Medical Center, is the corresponding author for the Blood Advances article.

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.


Advertisement

Advertisement



Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.